Centenary scientist, Claudio Counoupas, was invited by the Bill and Melinda Gates Foundation to present his research at the 3rd annual CTVD meeting, held in Seattle 21-23 June 2017.
About the CTVD
The Bill & Melinda Gates Foundation’s TB strategy addresses many of the factors associated with the TB epidemic. A new vaccine would provide the most effective way to decrease the incidence of TB, so our top priority is to explore innovative and accelerated approaches to vaccine development. However, the combined deployment of vaccines, diagnostics, and drugs is essential to addressing the epidemic. A vaccine that is able to interrupt TB transmission is likely to be the most impactful tool in efforts to control the disease.
To address innovation, collaboration and coordination in the upstream space, the foundation created the Collaboration for TB Vaccine Discovery (CTVD) – an international network of scientists and experts dedicated to foster innovation and collaboration in the up-stream TB vaccine discovery and development space. Early sharing of scientific information and standardization of laboratory techniques and data analysis are prominent themes.
The Centre for Research Excellence in Tuberculosis Control’s 2018 Symposium to be held 31 May and 1 June at the Centenary Institute.
Collectively our impact will be greater than we can achieve on own – supporting the career progression of our staff and students.
Study reveals gene therapy reduces or eliminates need for transfusions in transfusion-dependent β-thalassemia patients.